1. Home
  2. Disease & Disorders
  3. Norwalk, CT
  4. The Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation is ranked among disease & disorders organizations in Norwalk, CT, with an America's Best Score of 65 out of 100, based on its 2025 Form 990.

  • Norwalk, CT
  • Tax-exempt since 1998
  • EIN: 06-1504413
themmrf.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
65OF 100 Ranked in Norwalk Disease & Disorders How this score is calculated

Organization summary

The Multiple Myeloma Research Foundation is a 501(c)(3) organization, classified under Disease & Disorders (NTEE G50). Contributions are tax-deductible.

383 Main Ave Ste 7, Norwalk, CT 06851-1544

Among the 3 scored disease & disorders organizations in Norwalk, The Multiple Myeloma Research Foundation holds 16.6 months of operating reserves (peer median 16.6 months), runs a typical yearly deficit of 6.4% (peers: deficit of 6.4%), and has cut spending 3.3% a year (peers: grown spending 15.7% a year).

In fiscal year 2025 it reported $36,523,356 in revenue and $34,651,131 in expenses, with contributions making up 72.9% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

The Multiple Myeloma Research Foundation (mmrf) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches, and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the mmrf has committed over $600 million for research, supported nearly 100 clinical trials and research studies, and helped bring over 15 fda-approved therapies to market, which have tripled the life expectancy of myeloma patients.

Largest programs · fiscal year 2025

  • The multiple myeloma research consortium (mmrc), the clinical research subsidiary of The Multiple Myeloma Research Foundation (mmrf), is a collaborative network of leading cancer centers driving cutting-edge clinical trials. The mmrf launched the horizon clinical trials program through the mmrc to drive progress for patients who need it most. Horizon trials use an adaptive platform design that all… Read more

    The multiple myeloma research consortium (mmrc), the clinical research subsidiary of The Multiple Myeloma Research Foundation (mmrf), is a collaborative network of leading cancer centers driving cutting-edge clinical trials. The mmrf launched the horizon clinical trials program through the mmrc to drive progress for patients who need it most. Horizon trials use an adaptive platform design that allows researchers to test several treatments at the same time and add new options as data becomes available. In 2025, the horizon one trial focused on relapsed/refractory myeloma exceeded many of its enrollment goals for its first treatment arm, which is testing dosing approaches for a bispecific antibody. The trial so far has enrolled more Black patients and older adultstwo groups that have historically been left out of researchthan most myeloma trials. Horizon one became the first-ever myeloma clinical trial in flint, Michigan, and it opened at 25 community hospitals and clinics last year. Also in 2025, 13 sites entered the start-up phase in the horizon two clinical trial focused on high-risk, newly diagnosed myeloma so they could fully open and begin screening patients in 2026.

    $6,096,220 spent · 22.3% of program spending
  • Data helps drive every breakthrough in myeloma. By building and sharing large, high-quality datasets, the mmrf is creating a launchpad for the next wave of treatments, improvements in care, and, ultimately, cures. In 2025, the mmrf launched its next innovation in data sharing: The mmrf virtual labtm. Virtual lab is now myeloma's largest, most-comprehensive data-sharing platform and brings all the… Read more

    Data helps drive every breakthrough in myeloma. By building and sharing large, high-quality datasets, the mmrf is creating a launchpad for the next wave of treatments, improvements in care, and, ultimately, cures. In 2025, the mmrf launched its next innovation in data sharing: The mmrf virtual labtm. Virtual lab is now myeloma's largest, most-comprehensive data-sharing platform and brings all the mmrf's data into one place. The platform and its robust data will empower researchers to ask bigger questions, test new hypotheses, and accelerate discoveries that improve outcomes for patients with myeloma.

    $2,669,588 spent · 9.8% of program spending
  • The mac program provides $21 million over 3 years to create multicenter translational research teams across global medical centers. Each of these three-year multicenter translational projects aim to foster collaboration and advance compelling hypotheses that are ready for rapid testing in clinical trials, a critical step in the mmrf's urgent pursuit of a cure for each and every myeloma patient. Th… Read more

    The mac program provides $21 million over 3 years to create multicenter translational research teams across global medical centers. Each of these three-year multicenter translational projects aim to foster collaboration and advance compelling hypotheses that are ready for rapid testing in clinical trials, a critical step in the mmrf's urgent pursuit of a cure for each and every myeloma patient. The grants are focused on two critical areas of unmet need: Optimizing first-line therapy for newly diagnosed high-risk myeloma and improving identification of high-risk smoldering myeloma (hr smm), an early, asymptomatic stage that can proceed to active myeloma. In 2025 the collaborating centers continued to make positive progress, showing that pooling resources and samples across a network of institutions dramatically improves the ability to drive meaningful results.

    $1,600,000 spent · 5.8% of program spending
  • Beyond the program expenses outlined above, the mmrf also supports a range of strategic initiatives aligned with its broader mission. This includes a robust portfolio of cutting-edge basic science and translational research aimed at identifying new therapeutic targets through genomics and proteomics; validation studies to explore promising compounds and treatment combinations; and innovative clini… Read more

    Beyond the program expenses outlined above, the mmrf also supports a range of strategic initiatives aligned with its broader mission. This includes a robust portfolio of cutting-edge basic science and translational research aimed at identifying new therapeutic targets through genomics and proteomics; validation studies to explore promising compounds and treatment combinations; and innovative clinical trials focused on novel and combination therapies.founded by patients, the mmrf is deeply committed to those impacted by myeloma: Patients, families, physicians, researchers, and investors. At the same time, the mmrf distinguishes itself through its bold and collaborative approach. We generate, analyze, and share the largest, most comprehensive set of high-quality myeloma data, making it publicly available to accelerate progress. By bringing together the right people, programs, and technologies, the mmrf is driving the rapid discovery of cures for each and every patient.

    $16,987,283 spent · 62.1% of program spending

Where each dollar went · fiscal year 2025

Of every dollar it spent, 79¢ went to programs, 3¢ to management and 18¢ to fundraising.

  • Programs $27,353,091
  • Management $1,191,036
  • Fundraising $6,107,004

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score65 / 100
DesignationRanked

Score breakdown

MeasureThis organizationPoints
Operating reserves16.6 mo; 4.7 mo in cash11.6 / 25
Financial balance (median margin)−6.4%10 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth−3.3% / yr5.9 / 15
Track record28 years10 / 10
Debt load23.6% of assets7.3 / 10
Total64.7 → 65
Spending on programs
Not scored; America's Best needs 65%+
79%Meets

Compared with Norwalk peers

MeasureThis organizationPeer median
Operating reserves16.6 mo16.6 mo
Typical margin−6.4%−6.4%
Spending growth−3.3% / yr+15.7% / yr
Debt load23.6%15.9%

Peers: the 3 Norwalk disease & disorders organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$36,523,356Fiscal year 20252022: $45,044,47420222023: $33,950,59020232024: $29,101,41420242025: $36,523,3562025
Expenses$34,651,131Fiscal year 20252022: $38,280,73020222023: $41,890,82920232024: $35,604,33720242025: $34,651,1312025
Total assets$62,872,951Fiscal year 20252022: $89,097,66120222023: $80,227,63220232024: $66,397,14820242025: $62,872,9512025
Total liabilities$14,844,396Fiscal year 20252022: $25,407,74720222023: $23,942,20820232024: $16,374,75520242025: $14,844,3962025
Fiscal year ending December 2025
Revenue$36,523,356
Expenses$34,651,131
Net income$1,872,225
Net assets$48,028,555

Notable sources of revenue

Percent of total revenue
Contributions$26,628,081
Program services$8,674,361
Investment income$1,150,050
Other (net)$70,864

Assets / debt

Total assets$62,872,951
Total liabilities$14,844,396
Net assets$48,028,555

Compensation

Not in our extract for this year.

Fiscal year ending December 2024
Revenue$29,101,414
Expenses$35,604,337
Net income−$6,502,923
Net assets$50,022,393

Notable sources of revenue

Percent of total revenue
Contributions$24,100,727
Program services$2,261,716
Investment income$2,238,351
Other (net)$500,620

Assets / debt

Total assets$66,397,148
Total liabilities$16,374,755
Net assets$50,022,393

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$33,950,590
Expenses$41,890,829
Net income−$7,940,239
Net assets$56,285,424

Notable sources of revenue

Percent of total revenue
Contributions$30,976,388
Program services$1,281,492
Investment income$1,692,518
Other (net)$192

Assets / debt

Total assets$80,227,632
Total liabilities$23,942,208
Net assets$56,285,424

Compensation

Not in our extract for this year.

Fiscal year ending December 2022
Revenue$45,044,474
Expenses$38,280,730
Net income$6,763,744
Net assets$63,689,914

Notable sources of revenue

Percent of total revenue
Contributions$42,022,114
Program services$2,152,800
Investment income$679,638
Other (net)$189,922

Assets / debt

Total assets$89,097,661
Total liabilities$25,407,747
Net assets$63,689,914

Compensation

Officers and key employees$3,961,065
Share of expenses10.3%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?